Ticker League

Climb Bio (CLYM) Free Cash Flow Bridge

Pinpoint what moved Climb Bio's FCF from TTM through Q1 2025 to TTM through Q1 2026 — operating cash flow shifts and capex changes, each driver sized in dollars.

Analysis
Capital Return

How this company returns cash to shareholders — buybacks, dividends, and stock splits.

TTM

FCF YoY

-83.32%

OCF YoY

-82.68%

Capex Change

+186.0K

FCF Conversion Δ

Free cash flow bridge for Climb Bio (CLYM) — TTM through Q1 2026 vs TTM through Q1 2025

Δ Free cash flow: -$24.3M

FCF bridge breakdown for Climb Bio (CLYM) — TTM through Q1 2026 vs TTM through Q1 2025

  • Prior Free Cash Flow-$29.2M
  • Operating Cash Flow-$24.1M
  • Capital Expenditure-$186K
  • Free Cash Outflow-$53.5M
Identity check: drivers reconcile to ΔNI within $0.00
Want to see how cash flow is built up?Cash Flow Waterfall

Frequently asked questions

Data & methodology

Explore more

Deep-dives across the income statement, cash flow, capital return, and valuation